Neuromuscular side effects of MEK inhibitors
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy clinical trials.
This study looks at nerve and muscle problems caused by MEK inhibitors, a type of cancer drug. Researchers want to learn more about these side effects by collecting cases from France and reviewing past studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had a nerve or muscle problem while taking a MEK inhibitor (alone or with another drug)
- You agree to let researchers collect your medical information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug (MEK inhibitor) to treat thickened heart muscle caused by a group of genetic conditions called RASopathies. It may help improve heart function in people with hypertrophic cardiomyopathy.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
This trial tests a new medicine called UX016 for people with GNE myopathy, a rare muscle-weakening disease. The goal is to see if it can help improve muscle strength and function.
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
This study tests whether a new drug called BMS-986504 is safe and effective for treating malignant peripheral nerve sheath tumors (MPNST) that cannot be surgically removed. The drug targets a specific genetic change (MTAP deletion) found in these tumors.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
Hear when a new Myositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.